JAK-STAT信号通路及其抑制剂在特应性皮炎治疗中的应用

doi:10.35541/cjd.20190282

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (8): 661-664.doi: 10.35541/cjd.20190282

JAK-STAT信号通路及其抑制剂在特应性皮炎治疗中的应用

张曾云鸥蔡新颖肖风丽

安徽医科大学第一附属医院皮肤性病科安徽医科大学皮肤病研究所，合肥 230022

收稿日期:2019-01-31 修回日期:2019-09-05 发布日期:2020-07-31
通讯作者: 肖风丽 E-mail:xiaofengli@126.com
基金资助:
安徽省自然科学基金（1708085MH217）；安徽省学术和技术带头人及后备人选学术科研活动资助项目（2017D141）

JAK-STAT signaling pathway and its inhibitors in the treatment of atopic dermatitis

Zhang Zengyunou, Cai Xinying, Xiao Fengli

Department of Dermatology and Venereology, The First Affiliated Hospital of Anhui Medical University, Institute of Dermatology, Anhui Medical University, Hefei 230022, China

Received:2019-01-31 Revised:2019-09-05 Published:2020-07-31
Contact: Xiao Fengli E-mail:xiaofengli@126.com
Supported by:
Anhui Provincial Natural Science Foundation （1708085MH217）; Anhui Provincial Academic Research Foundation of Academic and Technical Leaders and Reserve Candidates （2017D141）

摘要/Abstract

摘要： 【摘要】 Janus激酶信号转导和转录激活因子（JAK-STAT）信号通路在特应性皮炎（AD）免疫学通路中起着重要作用，阻断JAK-STAT信号通路的药物，如经典的JAK抑制剂托法替尼、鲁索利替尼等，已逐步应用到AD治疗的临床试验中，并取得较好的疗效。其他对JAK-STAT信号通路有抑制作用的因子，如apamin、dupilumab等也在治疗AD上显示出一定效果。本文对近年来JAK-STAT信号通路及其相关抑制剂研究进行综述。

关键词: 皮炎, 特应性, Janus激酶类, STAT转录因子类, JAK/STAT抑制剂

Abstract: 【Abstract】 Janus kinase-signal transducer and activator of transcription （JAK-STAT） signaling pathway plays an important role in immune pathways in atopic dermatitis （AD）. Drugs that block the JAK-STAT signaling pathway, such as classic JAK inhibitors tofacitinib, ruxolitinib, etc., have been gradually applied to the treatment of AD in clinical trials, and good clinical efficacy has been achieved. In addition, other inhibitors of the JAK-STAT signaling pathway, such as apamin and dupilumab, also show some efficacy in the treatment of AD. This review summarizes recent studies on the JAK-STAT signaling pathway and its inhibitors.

Key words: Dermatitis, atopic, Janus kinases, STAT transcription factors, JAK/STAT inhibitor

张曾云鸥蔡新颖肖风丽. JAK-STAT信号通路及其抑制剂在特应性皮炎治疗中的应用[J]. 中华皮肤科杂志, 2020,53(8):661-664. doi:10.35541/cjd.20190282

zhangZhang Zengyunou, Cai Xinying, Xiao Fengli. JAK-STAT signaling pathway and its inhibitors in the treatment of atopic dermatitis[J]. Chinese Journal of Dermatology, 2020, 53(8): 661-664.doi:10.35541/cjd.20190282

参考文献 36

［1］	Gandhi NA, Pirozzi G, Graham N. Commonality of the IL⁃4/IL⁃13 pathway in atopic diseases［J］. Expert Rev Clin Immunol, 2017,13（5）:425⁃437. doi: 10.1080/1744666X.2017.1298443.
［2］	Sullivan M, Silverberg NB. Current and emerging concepts in atopic dermatitis pathogenesis［J］. Clin Dermatol, 2017,35（4）:349⁃353. doi: 10.1016/j.clindermatol.2017.03.006.
［3］	Lee DE, Clark AK, Tran KA, et al. New and emerging targeted systemic therapies: a new era for atopic dermatitis［J］. J Dermatolog Treat, 2018,29（4）:364⁃374. doi: 10.1080/09546634. 2017.1373736.
［4］	Saleem MD, Oussedik E, D′Amber V, et al. Interleukin⁃31 pathway and its role in atopic dermatitis: a systematic review［J］. J Dermatolog Treat, 2017,28（7）:591⁃599. doi: 10.1080/09546634. 2017.1290205.
［5］	Lloyd CM, Snelgrove RJ. Type 2 immunity: expanding our view［J］. Sci Immunol, 2018,3（25）:eaat1604. doi: 10.1126/sciimmunol. aat1604.
［6］	Yagi R, Nagai H, Iigo Y, et al. Development of atopic dermatitis⁃like skin lesions in STAT6⁃deficient NC/Nga mice［J］. J Immunol, 2002,168（4）:2020⁃2027. doi: 10.4049/jimmunol.168.4. 2020.
［7］	Bao L, Shi VY, Chan LS. IL⁃4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: implication for atopic dermatitis［J］. Mol Immunol, 2012,50（1⁃2）:91⁃97. doi: 10.1016/j.molimm.2011.12.008.
［8］	Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class［J］. J Am Acad Dermatol, 2017,76（4）:736⁃744. doi: 10.1016/j.jaad.2016.12.005.
［9］	Alves de Medeiros AK, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases［J/OL］. PLoS One, 2016,11（10）:e0164080. doi: 10.1371/journal.pone.0164080.
［10］	Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial［J］. Br J Dermatol, 2016,175（5）:902⁃911. doi: 10.1111/bjd.14871.
［11］	Kostovic K, Gulin SJ, Mokos ZB, et al. Tofacitinib, an oral Janus Kinase inhibitor: perspectives in dermatology［J］. Curr Med Chem, 2017,24（11）:1158⁃1167. doi: 10.2174/1874467210666170113 104503.
［12］	Meyer DM, Jesson MI, Li X, et al. Anti⁃inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP⁃690,550, in rat adjuvant⁃induced arthritis［J］. J Inflamm （Lond）, 2010,7:41. doi: 10.1186/1476⁃9255⁃7⁃41.
［13］	Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib （CP⁃690,550）［J］. J Immunol, 2011,186（7）:4234⁃4243. doi: 10.4049/jimmunol.100 3668.
［14］	Kontzias A, Kotlyar A, Laurence A, et al. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease［J］. Curr Opin Pharmacol, 2012,12（4）:464⁃470. doi: 10.1016/j.coph.2012. 06.008.
［15］	Kubo S, Nakayamada S, Sakata K, et al. Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system［J］. Front Immunol, 2018,9:1510. doi: 10.3389/fimmu.2018.01 510.
［16］	Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate［J］. J Am Acad Dermatol, 2015,73（3）:395⁃399. doi: 10.1016/j.jaad.2015.06.045.
［17］	Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis［J］. N Engl J Med, 2010,363（12）:1117⁃1127. doi: 10.1056/NEJMoa1002028.
［18］	Verstovsek S, Mesa RA, Gotlib J, et al. A double⁃blind, placebo⁃controlled trial of ruxolitinib for myelofibrosis［J］. N Engl J Med, 2012,366（9）:799⁃807. doi: 10.1056/NEJMoa1110557.
［19］	Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis［J］. Drugs, 2015,75（3）:297⁃308. doi: 10.1007/s40265⁃015⁃0351⁃8.
［20］	He H, Guttman⁃Yassky E. JAK inhibitors for atopic dermatitis: an update［J］. Am J Clin Dermatol, 2019,20（2）:181⁃192. doi: 10.1007/s40257⁃018⁃0413⁃2.
［21］	Guttman⁃Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate⁃to⁃severe atopic dermatitis: a phase 2 parallel, double⁃blinded, randomized placebo⁃controlled multiple⁃dose study［J］. J Am Acad Dermatol, 2019,80（4）:913⁃921.e9. doi: 10.1016/j.jaad.2018.01.018.
［22］	Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE⁃052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents［J］. Exp Dermatol, 2018,27（1）:22⁃29. doi: 10.1111/exd.13370.
［23］	Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE⁃052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling［J］. J Allergy Clin Immunol, 2015,136（3）:667⁃677.e7. doi: 10.1016/j.jaci.2015.03.051.
［24］	Nakagawa H, Nemoto O, Yamada H, et al. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE⁃052 （a novel Janus kinase inhibitor） ointment in Japanese healthy volunteers and patients with atopic dermatitis［J］. J Dermatol, 2018,45（6）:701⁃709. doi: 10.1111/1346⁃8138.14322.
［25］	Wright HL, Cross AL, Edwards SW, et al. Effects of IL⁃6 and IL⁃6 blockade on neutrophil function in vitro and in vivo［J］. Rheumatology （Oxford）, 2014,53（7）:1321⁃1331. doi: 10.1093/rheumatology/keu035.
［26］	Kim WH, An HJ, Kim JY, et al. Apamin inhibits TNF⁃α⁃ and IFN⁃γ⁃induced inflammatory cytokines and chemokines via suppressions of NF⁃κB signaling pathway and STAT in human keratinocytes［J］. Pharmacol Rep, 2017,69（5）:1030⁃1035. doi: 10.1016/j.pharep.2017.04.006.
［27］	Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. N Engl J Med, 2014,371（2）:130⁃139. doi: 10.1056/NEJMoa1314768.
［28］	Simpson EL, Gadkari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient⁃reported outcomes （PROs）: a phase IIb, randomized, placebo⁃controlled, clinical trial in adult patients with moderate to severe atopic dermatitis （AD）［J］. J Am Acad Dermatol, 2016,75（3）:506⁃515. doi: 10.1016/j.jaad.2016.04.054.
［29］	Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate⁃to⁃severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo⁃controlled, dose⁃ranging phase 2b trial［J］. Lancet, 2016,387（10013）:40⁃52. doi: 10.1016/S0140⁃6736（15）00388⁃8.
［30］	Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis［J］. Expert Rev Clin Pharmacol, 2018,11（5）:467⁃474. doi: 10.1080/17512433.2018.1449642.
［31］	Hou DD, Di ZH, Qi RQ, et al. Sea buckthorn （hippophaë rhamnoides L.） oil improves atopic dermatitis⁃like skin lesions via inhibition of NF⁃κB and STAT1 activation［J］. Skin Pharmacol Physiol, 2017,30（5）:268⁃276. doi: 10.1159/000479 528.
［32］	Tsuji G, Takahara M, Uchi H, et al. Identification of ketoconazole as an AhR⁃Nrf2 activator in cultured human keratinocytes: the basis of its anti⁃inflammatory effect［J］. J Invest Dermatol, 2012,132（1）:59⁃68. doi: 10.1038/jid.2011.194.
［33］	Takemura M, Nakahara T, Hashimoto⁃Hachiya A, et al. Glyteer, soybean tar, impairs IL⁃4/Stat6 signaling in murine bone marrow⁃derived dendritic cells: the basis of its therapeutic effect on atopic dermatitis［J］. Int J Mol Sci, 2018,19（4）:1169. doi: 10.3390/ijms19041169.
［34］	Park JW, Lee HS, Lim Y, et al. Rhododendron album blume extract inhibits TNF⁃α/IFN⁃γ⁃induced chemokine production via blockade of NF⁃κB and JAK/STAT activation in human epidermal keratinocytes［J］. Int J Mol Med, 2018,41（6）:3642⁃3652. doi: 10.3892/ijmm.2018.3556.
［35］	Lee JH, Choi CS, Bae IH, et al. A novel, topical, nonsteroidal, TRPV1 antagonist, PAC⁃14028 cream improves skin barrier function and exerts anti⁃inflammatory action through modulating epidermal differentiation markers and suppressing Th2 cytokines in atopic dermatitis［J］. J Dermatol Sci, 2018. doi: 10.1016/j.jdermsci.2018.04.017.
［36］	Kang NJ, Han SC, Kang GJ, et al. Diphlorethohydroxycarmalol inhibits interleukin⁃6 production by regulating NF⁃κB, STAT5 and SOCS1 in lipopolysaccharide⁃stimulated RAW264.7 cells［J］. Mar Drugs, 2015,13（4）:2141⁃2157. doi: 10.3390/md13042141.

[1]	刘小扬赵琰蔡林张建中. 银屑病患者白细胞介素17拮抗剂治疗后出现特应性皮炎样皮疹4例分析与文献回顾[J]. 中华皮肤科杂志, 2023, 56(9): 845-848.
[2]	郭昊刘辉张丽朱冠男王平姚志荣高兴华陈耀龙. 特应性皮炎诊疗指南（专科医生版本、全科医生版本和患者版本）计划书[J]. 中华皮肤科杂志, 2023, 56(9): 809-814.
[3]	陈春里闫思聿王丹高丽华谭丽娜唐四元刘伟曾金容鲁建云. 酸化脂肪酸酯治疗特应性皮炎样模型小鼠的疗效及机制初探[J]. 中华皮肤科杂志, 2023, 56(9): 822-831.
[4]	王珊王星宇舒虹张斌石航杨欢钱秋芳马红艳梁源赵牧童申春平焦磊田晶汪洋谷盈孙婧刘盈李萍王华马琳. 克立硼罗软膏早期缓解儿童特应性皮炎临床症状及改善缓解期临床症状的多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(9): 815-821.
[5]	申春平李萍罗晓燕梁源刘盈赵牧童王珊田晶焦磊汪洋罗珍余时娟方晓王华马琳. [开放获取] 某润肤霜联合周末外用糖皮质激素对延缓儿童特应性皮炎维持期疾病复发的随机、空白对照、多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(8): 756-762.
[6]	徐西利李东宁段函王菲. 青少年及成人特应性皮炎患者血浆氨基酸代谢水平分析[J]. 中华皮肤科杂志, 2023, 56(8): 742-750.
[7]	宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723.
[8]	张晓东汪蔓雅朱英杰骆天德刘小明. 荧光染色法在面部皮肤蠕形螨检查中的应用评估[J]. 中华皮肤科杂志, 2023, 56(8): 766-769.
[9]	渠莉田陈锦丛程波苏惠春. 特应性皮炎患者外周血单个核细胞转谷氨酰胺酶2的表达与相关炎症因子及疾病严重程度的相关性[J]. 中华皮肤科杂志, 2023, 56(7): 651-656.
[10]	蒋晓妍高敏张晓艳刘宁远. 白细胞介素17和白细胞介素23拮抗剂治疗脓疱型银屑病研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 689-692.
[11]	陈奇权孔敏敏杨显杰王欢李健张名望宋志强. [开放获取] 慢性诱导性荨麻疹患者168例过敏原反应性和特应性病史的临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 496-503.
[12]	苏畅隋秀丽刘瑞玲曹毅群姜虹严彩蓉王惠平亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517.
[13]	李嘉祺叶枫鞠强. 表皮葡萄球菌共生性稳态与皮肤疾病[J]. 中华皮肤科杂志, 2023, 56(5): 459-462.
[14]	洪芷榆谢红付李吉黄莹雪. 发光二极管红黄光治疗急性发作期面部炎症性皮肤病的支付意愿分析[J]. 中华皮肤科杂志, 2023, 56(4): 325-329.
[15]	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组中国老年保健医学研究会皮肤科分会中国中药协会皮肤病药物研究专业委员会. [开放获取] 湿疹皮炎类皮肤病中西医结合药物治疗专家共识[J]. 中华皮肤科杂志, 2023, 56(4): 287-293.

JAK-STAT信号通路及其抑制剂在特应性皮炎治疗中的应用

JAK-STAT signaling pathway and its inhibitors in the treatment of atopic dermatitis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

Metrics

本文评价

推荐阅读 10